|1.||Ito, Morihiro: 4 articles (12/2015 - 09/2008)|
|2.||Nishio, Machiko: 4 articles (12/2015 - 09/2008)|
|3.||Komada, Hiroshi: 4 articles (12/2015 - 09/2008)|
|4.||Tsurudome, Masato: 4 articles (12/2015 - 09/2008)|
|5.||Kawano, Mitsuo: 3 articles (08/2013 - 09/2008)|
|6.||Nosaka, Tetsuya: 2 articles (12/2015 - 08/2013)|
|7.||El-Deeb, Ibrahim M: 2 articles (03/2015 - 09/2014)|
|8.||von Itzstein, Mark: 2 articles (03/2015 - 09/2014)|
|9.||Guillon, Patrice: 2 articles (03/2015 - 09/2014)|
|10.||Tappert, Mary M: 2 articles (08/2013 - 12/2011)|
01/01/2010 - "The immunogenic properties of the construct were evaluated using two systems: rabbit immunization to obtain sera for detection of the HN protein and neutralization of MuV infection, and hamster immunization to evaluate protection against MuV infection. "
05/01/1988 - "A MAb to the Sendai virus HN protein was found to confer protection against PIV3 brain infection."
09/25/2014 - "Hemagglutinin-neuraminidase glycoprotein is a key protein in viral infection, and its inhibition has been a target for 2-deoxy-2,3-didehydro-d-N-acetylneuraminic acid (Neu5Ac2en)-based inhibitor development. "
08/01/2014 - "Although virus neutralization (VN) test showed that poor flock immunity due to vaccination failure or partial and non-uniform immunization maybe the major factors involved in the mechanism of breakthrough infection of the Japanese field strains, approximately two to threefold decrease in the VN titers of the field NDV strains possessing a point mutation (E347K or E347G) at the linear epitope of the HN protein was observed, as compared to vaccine strain B1 and field strain 2440/69, which lack the point mutation. "
01/01/2012 - "The inhibition of viral penetration experiments with a wild-type NDV strain supported this result, as these experiments demonstrated a 48% decrease in viral infection as well as reduced HN protein expression. "
|2.||Paramyxoviridae Infections (Parainfluenza)
12/15/2015 - "Virus-specific interaction between the attachment protein (HN) and the fusion protein (F) is prerequisite for the induction of membrane fusion by parainfluenza viruses. "
09/25/2012 - "Considering together the crystal structures of HN from different paramyxoviruses, varying energy requirements for fusion activation, F activation involving the parainfluenza virus 5 HN stalk domain, and properties of a chimeric paramyxovirus HN protein, we propose a simple model for the activation of paramyxovirus fusion."
09/25/2012 - "We provide evidence that the receptor-binding globular head domain of the paramyxovirus parainfluenza virus 5 HN protein is entirely dispensable for F activation. "
12/01/2009 - "For the paramyxovirus parainfluenza virus type 5 (PIV-5), this fusion involves an attachment protein (HN) and a class I viral fusion protein (F). "
01/01/2005 - "We analyzed whether the human parainfluenza 3 (HPF3) virus hemagglutinin-neuraminidase glycoprotein (HN) might influence DC maturation. "
07/01/1991 - "It was concluded that the HN protein of NDV expressed as a subunit by a recombinant baculovirus was protective against Newcastle disease."
01/01/1989 - "This report describes an ELISA blocking test using a peroxidase-labelled monoclonal antibody which binds to the HN protein of Newcastle disease (NDV). "
01/01/2011 - "To investigate the relationship between the selective pressure and the sequence variation of the hemagglutinin-neuraminidase (HN) protein, we performed the positive selection analysis by estimating the ratio of non-synonymous to synonymous substitutions with 132 complete HN gene sequences of Newcastle disease viruses (NDVs) isolated in China. "
03/01/2010 - "The hemagglutinin-neuraminidase (HN) protein of Newcastle disease virus (NDV) plays an important role in the pathogenesis of Newcastle disease (ND). "
12/01/2004 - "A quantification assay for the Haemagglutinin-Neuraminidase (HN) protein of Newcastle Disease Virus (NDV) has been developed at CIDC-Lelystad as a candidate in vitro potency test for inactivated Newcastle disease (ND) vaccines. "
12/01/2014 - "Although the putative HN protein sequence differed by 4.8-5.5% in relation to Jeryl Lynn 5 strain (the main strain used in the vaccination program in this region), the vaccine was effective, and dramatically reduced the incidence of mumps over the following years. "
01/01/1989 - "Comparison of the mumps HN protein sequence with the HN protein sequences of Sendai virus, simian-virus 5 (SV5), parainfluenza virus type 3 and Newcastle disease virus (NDV) shows two major homology regions, one region near the middle of the protein and the other in the second half of the molecule. "
01/01/2014 - "Dependence on serology to evaluate mumps vaccines may have overemphasized the conservation of one neutralizing antibody epitope, at the expense of monitoring other related changes in the HN protein that could affect recall responses. "
08/01/2010 - "On the basis of antitumor effect in vitro, the aim of this study is to investigate the anti-tumor immunity effect of HN protein in vivo. "
08/01/2010 - "The anti-tumor immunity of Newcastle disease virus HN protein is influenced by differential subcellular targeting. "
08/01/2010 - "[Anti-tumor immunity of Newcastle disease virus HN protein is influenced by differential subcellular targeting]."
07/01/2010 - "The anti-tumor effect of Newcastle disease virus HN protein is influenced by differential subcellular targeting."
08/01/2004 - "HN protein located on the surface of tumor cells and mediated the specific repulsion to tumor cells; the antitumor efficacy increased after the combined application of NDV and its HN gene."
|3.||4- dichloromethanesulfonylamino- 2,3- didehydro- 2,3,4,5- tetradeoxyglycerogalacto- 2- nonulopyranosic acid
|4.||4- zido- 5- isobutyrylamino- 2,3- didehydro- 2,3,4,5- tetradeoxyglycerogalacto- 2- nonulopyranosic acid
|7.||N-Acetylneuraminic Acid (Sialic Acid)
|8.||Proteins (Proteins, Gene)